Acute Respiratory Distress Syndrome (ARDS) Market Overview 2024-2033 - Share, Size, Insights, Forecast

The new report published by The Business Research Company, titled Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the acute respiratory distress syndrome (ards) market size has grown rapidly in recent years. It will grow from $1.17 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

Impact Of Increasing Pneumonia Prevalence On The Acute Respiratory Distress Syndrome (ARDS) Market
The growing prevalence of pneumonia is expected to propel the growth of the acute respiratory distress syndrome (ARDS) market going forward. Pneumonia is an infection that affects one or both lungs, causing the lungs' air sacs, or alveoli, to fill up with fluid or pus. Pneumonia causes an inflammatory reaction in the lungs, increasing blood vessel permeability and fluid leakage into the alveoli. This fluid buildup interferes with the exchange of oxygen and carbon dioxide, causing respiratory discomfort. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2021, the number of deaths due to pneumonia in the United States was 41,309, with a mortality rate of 12.4 deaths per 100,000 population. Therefore, the growing prevalence of pneumonia drives the growth of the acute respiratory distress syndrome (ARDS) market.

Innovative Drug Development Initiatives Transforming The Acute Respiratory Distress Syndrome (ARDS) Market
Major companies operating in the acute respiratory distress syndrome (ARDS) market are focusing on developing innovative drugs and supplements, such as Aviptadil, HSP90 inhibitors and others to sustain their position in the market. Aviptadil is a synthesized vasoactive intestinal peptide (VIP) that binds specifically to receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an India-based pharmaceutical manufacturing company, launched Aviptadil to treat acute respiratory distress syndrome. Aviptadil, a vasoactive intestinal peptide supplement, improves breathing and lowers mortality in ARDS patients. This is accomplished through Aviptadil's ability to protect and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis and suppress IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.

The acute respiratory distress syndrome (ards) market covered in this report is segmented -

1) By Type: Diagnosis; Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
3) By Severity: Mild; Moderate; Severe
4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13005&type=discount

Major players in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

Contents of the report:
1. Executive Summary
2. Acute Respiratory Distress Syndrome (ARDS) Market Report Structure
3. Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies
4. Acute Respiratory Distress Syndrome (ARDS) Market - Macro Economic Scenario
5. Acute Respiratory Distress Syndrome (ARDS) Market Size And Growth
…..
27. Acute Respiratory Distress Syndrome (ARDS) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.